# Marker Therapeutics, Inc. (MRKR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $22M  
**Price:** $1.43 (+1.42%)

> Marker Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapeutic solutions in the pharmaceuticals and biotech sector. Headquartered in Houston, Texas, and founded in 1999, the company specializes in advancing treatments designed to address significant unmet medical needs. Marker Therapeutics operates within the competitive biotechnology industry, where it engages in research, development, and commercialization of therapeutic products. The company's work spans clinical and preclinical stages, targeting disease areas where novel biological approaches can provide meaningful patient benefits. As a publicly traded biotechnology firm, Marker Therapeutics is subject to the rigorous regulatory and scientific standards that govern drug development and approval. The company maintains operations focused on translating scientific discoveries into effective treatments, contributing to the broader landscape of modern therapeutic innovation and advancing healthcare solutions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4M | — | -$13M | -$12M | — |
| 2024 | $7M | — | -$11M | -$11M | — |
| 2023 | $3M | — | -$15M | -$8M | — |
| 2022 | $4M | — | -$20M | -$30M | — |
| 2021 | — | — | -$39M | -$42M | — |
| 2020 | $500,000 | — | -$29M | -$29M | — |
| 2019 | $213,194 | — | -$23M | -$21M | — |
| 2018 | $205,994 | — | -$148M | -$148M | — |
| 2017 | $183,064 | — | -$11M | -$11M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $19M | $2M | $17M | $16M | — |
| 2024 | $22M | $3M | $19M | $19M | — |
| 2023 | $17M | $3M | $14M | $15M | — |
| 2022 | $34M | $15M | $20M | $12M | — |
| 2021 | $68M | $24M | $44M | $42M | — |
| 2020 | $46M | $18M | $27M | $21M | — |
| 2019 | $46M | $2M | $44M | $44M | — |
| 2018 | $62M | $3M | $59M | $62M | — |
| 2017 | $5M | $2M | $4M | $5M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$12M | — | — |
| 2024 | -$11M | — | — |
| 2023 | -$16M | — | — |
| 2022 | -$27M | — | — |
| 2021 | -$27M | — | — |
| 2020 | -$20M | — | — |
| 2019 | -$18M | $374,983 | -$19M |
| 2018 | -$14M | $147,668 | -$15M |
| 2017 | -$8M | — | -$8M |
| 2016 | -$7M | — | — |
| 2015 | -$4M | — | — |
| 2014 | -$2M | — | — |
| 2013 | -$694,583 | — | — |
| 2012 | -$2M | — | — |
| 2011 | -$1M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/MRKR)